ACTU
Actuate Therapeutics, Inc. Common stock · Healthcare
Insiders sold $1.6M of Actuate Therapeutics, Inc. Common stock in the last 12 months and bought none
ACTU over the last year
ACTU after insider buys
3 months after each buy, from the first price a copier could get.
1 buy has 3 months of prices so far. A record shows here at 3.
Every filing
8 insider filings since 2024, newest first
Todd S Thomson · Director and 10% owner
Bios Equity Cof, LP · Director and 10% owner
Leslie W. Kreis · Director and 10% owner
Aaron G.l. Fletcher · Director and 10% owner
Bios Equity Cof, LP · Director and 10% owner
Aaron G.l. Fletcher · Director and 10% owner
Leslie W. Kreis · 10% owner
Todd S Thomson · 16.4% Owner
About Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.